STOPCAP
Maximising patient benefit through enhanced evaluation of therapies and better characterisation of metastatic hormone-sensitive prostate cancer
Improving our understanding of metastatic prostate cancer and the effects of current and new treatments
What was this study about?
We want to find out which treatments for metastatic hormone-sensitive prostate cancer are the most effective, and for which men. We will do this by combining results and (anonymous) patient data from clinical trials to find out which characteristics of a man and his cancer are most useful for predicting his prognosis and his response to treatments.
We will also look for reliable early measures of whether a treatment is working, which can be used to shorten future trials, so men can access newer treatments sooner than they do now.
Finally, we will also try to ensure that the most effective treatments are used in clinical practice.
The STOPCAP Programme has been ongoing since 2018.
Visit this page to see a summary of the results so far.
For more information, visit:
What difference did this study make?
Please click below for more information about STOPCAP results, so far:
- Docetaxel, systematic review and aggregate data meta-analysis (Lancet Onc 2016)
- Bisphosphonates, systematic review and aggregate data meta-analysis (Lancet Onc 2016)
- Abiraterone, systematic review and aggregate data meta-analysis, (EJC 2017)
- Aggregate data network meta-analysis, (Annals Onc 2018)
- Prostate RT, systematic review and aggregate data meta-analysis, (Eur Urol 2019)
- Docetaxel, systematic review and individual participant data meta-analysis (Lancet Onc 2023)
Type of study
Meta-analyses
Contact details
Who funded the study?
STOPCAP is funded by Prostate Cancer UK.
When did it take place?
This programme of research is ongoing.
Where did it take place?
The programme is led by the MRC Clinical Trials Unit at University College London, and brings together the results of trials carried out worldwide.
Who was included?
Trials that randomised men with metastatic hormone-sensitive prostate cancer.
Related News
Spotlight on our research at ESMO Congress 2025
06 Oct 2025
'25 at 25': Framework for Adaptive Meta-analysis (FAME) for timely, reliable and thorough results
29 Oct 2024
New podcast episode: Who benefits most from a treatment?
12 Mar 2024
New prostate cancer treatments could reach men sooner
22 Feb 2024
More News...